Skip to main content

Want a detailed portfolio tracker?

TMDX
NASDAQ
$74.29

Transmedics Group Inc (TMDX)

TransMedics Group, Inc., a commercial-stage medical technology company, is dedicated to transforming organ transplant therapy for patients with end-stage organ failure in the United States and internationally. The company is headquartered in Andover, Massachusetts.
Website: https://www.transmedics.com
68 analysts
Buy
Target: $114 (+53.45%)

Market Cap

$2.60B

PEG Ratio

0.06

Revenue 5Y CAGR

+100.69%

P/E Ratio

15.00

Price Chart

Valuation
Market Cap$2.60B
P/E15.00
Forward P/E37.45
PEG0.06
P/S4.10
P/B5.22
Profitability
Total Revenue (TTM)$636M
Gross Profit (TTM)$376M
EBITDA$127M
Profit Margin4.2%
Operating Margin7.6%
EPS$5.02
Financial Health
Debt-to-Equity3%
Free Cash Flow Yield5.81%
Growth & Risk
Revenue 5Y CAGR+100.69%
Beta (5Y)1.21
Sharpe Ratio-0.49